Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
about
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activityImproved endpoints for cancer immunotherapy trialsCTLA-4 blockade: therapeutic potential in cancer treatmentsFc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaImmune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsThermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?A primer on tumour immunology and prostate cancer immunotherapyImmunotherapy: New Strategies for the Treatment of Gynecologic MalignanciesNovel technologies and emerging biomarkers for personalized cancer immunotherapyPredictive factors for immunotherapy in melanomaIntegrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyMelanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapyImmunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsB7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer lookImmune Checkpoint Blockade in Cancer TherapyTherapeutic cancer vaccines: past, present, and futureImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerImmunotherapy in the treatment of non-small cell lung cancerAntibody-based immunotherapy for ovarian cancer: where are we at?Tumor infiltrating lymphocytes in ovarian cancerAdvances of immunotherapy in small cell lung cancerDistinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsUpdate on immune checkpoint inhibitors in gynecological cancersThe role of immune checkpoint inhibition in the treatment of ovarian cancerCancer immunotherapy comes of ageStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumabIpilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trialQuantitative monitoring of mouse lung tumors by magnetic resonance imaging.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironmentFc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Active immunotherapy induces antibody responses that target tumor angiogenesis.Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cellsImmunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationAbscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
P2860
Q21245463-C2AD041A-3FA3-45C8-BB25-F1508FC3A1B0Q24603112-0FC370C2-D3D5-4FEF-96E1-35D43E06B8EEQ24622666-C6F7BDC0-4754-4794-A906-EE891E73B886Q24629841-C3FBD6D3-2C78-4856-8366-0CBC0BFEC699Q26742047-0CA9A5E5-97A3-4CC4-B85D-CBFB729DEF66Q26750649-9BC6917A-A2D9-4F44-AF66-3A83CA72210CQ26751230-6D4F49E7-A543-43E3-B348-A89EF5C9020EQ26765697-3A06D5FB-A0E3-4208-8DCF-64822A1BED86Q26770607-C05A1FAF-6B40-4176-A3D6-4B746B5BEA35Q26770780-5B564FFE-18F5-40C5-9BA4-82BCC30B4731Q26778765-8AF16200-72DC-4BA0-A840-FD5D7E225487Q26783783-2AA7068D-9880-47D8-B01C-CCAE28DE0C70Q26798404-31A0AFDB-F3A9-4EA2-A81E-80E7CEE3BE49Q26799812-4BD7A819-9828-41BD-95FD-CFDBBC652942Q26824446-9CBFBEB0-913B-4D21-9283-264695E28EB2Q26830509-A5DD0F81-D493-4BF5-A6AE-3EEBE08161A0Q26863283-2B70B616-CDBB-41FE-82A1-B64450B1F7D5Q26996829-1DED8DD8-7544-4457-A6F5-10F25783A3BAQ27000382-937CF707-3F8E-4F41-A2C2-30355C1E9A6DQ27000514-B1BA0D67-0E3B-47B0-ACE0-AEB94AC539DEQ27021878-6CF8F784-F702-453B-BD21-B3D542E9C215Q27027662-DA04DAB2-EB2E-4357-9840-B0E5EC891504Q27438176-A58F7E23-C4B5-4B38-A1D7-5CAD575EF40DQ28076497-FDA2881D-EF96-4873-9520-A91679C10714Q28077924-618B0590-7039-4B90-8F04-5CF5A2DC5633Q29619918-8EB28785-EC52-425D-B167-42C95565B7F7Q30274619-390785A8-A5A1-48D8-9336-229882781B2DQ30407940-C42F0656-35A8-4922-85C4-AB97F58A1CA4Q30560325-FC1E9B16-D9AA-4349-984E-57B85898C4C8Q30846001-030FD439-01BF-4CC9-BEC1-C3655BD34557Q33386521-B0969F1D-FB45-4C4A-9B80-0B520C298D96Q33564510-D174FD86-C6F9-49A0-A76D-C19509BD747AQ33671344-2DC6E568-7BA0-426D-8E33-EA4AF0904AE2Q33707098-ACB24AEA-CC61-4435-A74B-EE22D78FBDC2Q33772446-9D01105F-B3B7-4CA2-879B-4DE4C0A0C444Q33830113-C5788981-7349-4F54-ABD0-A67C59C026D3Q33834432-A0A4578D-D0DD-4165-A875-B56B8141B883Q33848077-64FD0B54-03F5-4A5A-9426-CDD608F48DB1Q33930593-F4EB8D3E-03AF-4F84-AACA-9CF6CB80FEDAQ33939202-45097EF4-838B-415A-8174-BFEAAED0E58C
P2860
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@ast
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@en
type
label
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@ast
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@en
prefLabel
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@ast
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@en
P2093
P2860
P921
P356
P1476
Immunologic and clinical effec ...... ly vaccinated cancer patients.
@en
P2093
Alan Korman
Andrea Kruse
Christine Canning
Darryl A Oble
David Lautz
Donna Neuberg
F Stephen Hodi
Frank G Haluska
Glenn Dranoff
Israel Lowy
P2860
P304
P356
10.1073/PNAS.0712237105
P407
P577
2008-02-19T00:00:00Z